Comparison of empirical use of low dose aspirin and enoxaprin in the treatment of unexplained recurrent pregnancy loss

Sunil Kumar Juneja; Pooja Tandon; Gagandeep Kaur; Bakul Kapoor; Guneet Singh Sidhu

doi:10.18203/2320-1770.ijrcog20200889

Authors

Sunil Kumar Juneja Department of Obstetrics and Gynecology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Pooja Tandon Department of Obstetrics and Gynecology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Gagandeep Kaur Department of Obstetrics and Gynecology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Bakul Kapoor Department of Obstetrics and Gynecology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Guneet Singh Sidhu Department of Obstetrics and Gynecology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20200889

Keywords:

Aspirin, Enoxaparin, Low molecular weight heparin, Pregnancy, Recurrent, Unexplained

Abstract

Background: Recurrent pregnancy losses have commonly been defined as three or more consecutive spontaneous pregnancy losses. About 1-2% of women suffer from recurrent miscarriages. The cause is multifactorial such as uterine anomalies, endocrine disorders, immunological causes, infections, chromosomal anomalies and maternal autoimmune diseases. In 50-60% of cases recurrent pregnancy losses, the cause remains unclear. Objective of this study was to compare the maternal and fetal outcome in patients with unexplained recurrent pregnancy loss treated with LMWH (Enoxaparin) vs Aspirin during pregnancy.

Methods: Women with 3 or more pregnancy losses, aged between 18-40 years, booked for antenatal care and delivery in our hospital between January 2012 and December 2016 were followed till 6 months after delivery.

Results: A total number of 146 women were assessed for eligibility. We had 62 women in Group A (aspirin group) and 84 women in Group E (enoxaparin group). Enoxaparin was given to all those ladies who had taken aspirin in previous pregnancies with no live outcome. Good neonatal outcome was observed with Enoxaparin.

Conclusions: Live birth rates did not show significant difference between the two study groups. But empirical use of enoxaparin in patients with no live birth who have taken low dose aspirin in previous pregnancy had shown improved results, so enoxaparin should be used empirically as a first line agent in such cases.

Metrics

Metrics Loading ...

References

Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod. 2006;21:2216-22.

Salat-Baroux J. Recurrent spontaneous abortions. Reprod Nutr Dev. 1988;28:1555-68.

Tulppala M, Palosuo T, Ramsay T, Miettinen A, Salonen R, Ylikorkala O. A prospective study of 63 couples with a history of recurrent spontaneous abortion: contributing factors and outcome of subsequent pregnancies. Hum Reprod. 1993;8(5):764-770.

Christiansen OB, Andersen AM, Bosch E, Daya S, Delves PJ, Hviid TV, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril. 2005;83:821-39.

Regan l, Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14:839-54.

Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361:901-8.

Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril. 2006;86:362-26.

Duhl AJ, Paidas MJ, Ural SH. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007;197:457.

Omri A, Delaloye JF, Anderson H, Bachman F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost. 1989;61:55-6.

Stirrat GM. Recurrent miscarriage: definition and epidemiology. Lancet. 1990;336:673-5.

Berry CW, Bramabati B, Eskes TKAB, Exalto N, Fox H, Geraedts JPM, et al. The euro team early pregnancy (ETEP) protocol for recurrent miscarriage. Hum Reprod. 1995;10:1516-20.

Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod. 1999;14:2868-71.

Franssen MT, Korevaar JC, Leschot NJ, Bossuyt PM, Knegt AC, Gerssen-Schoorl KB, et al. Selective chromosome analysis in couples with two or more miscarriages: case-control study. BMJ. 2005;331:137-9.

Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361:901-8.

Quenby S, Kalumbi C, Bates M, Farquharson R, Vince G. Prednisolone reduces preconceptual natural killer cells in women with recurrent miscarriage. Fertil Steril. 2005;84:980-4.

Christiansen OB, Nybo Andersen AM, Bosch E. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril. 2005;83(4):821-39.

Flood K, Peace A, Kent E, Tedesco T, Dicker P, Geary M, et al. Platelet reactivity and pregnancy loss. Am J Obstet Gynecol. 2010;203:281.

Van Horn, JT, Craven C, Ward K, Branch DW, Silver RM. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid like syndromes. Placenta. 2004;25:642-8.

Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Human Reprod. 1997;12:2061-5.

Walport MJ. Complement. N Engl J Med. 2001;344:1058-66.